Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
14,475,915
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
10,790,279
-
Shares change
-
-279,751
-
Total reported value, excl. options
-
$150,951,040
-
Value change
-
-$5,227,678
-
Put/Call ratio
-
0.56%
-
Number of buys
-
25
-
Number of sells
-
-51
-
Price
-
$13.99
Significant Holders of Inhibrx Biosciences, Inc. - Common Stock (INBX) as of Q1 2025
114 filings reported holding INBX - Inhibrx Biosciences, Inc. - Common Stock as of Q1 2025.
Inhibrx Biosciences, Inc. - Common Stock (INBX) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10,790,279 shares
of 14,475,915 outstanding shares and own 75% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (1,787,705 shares), Sanofi (1,157,926 shares), PERCEPTIVE ADVISORS LLC (1,064,026 shares), HighTower Advisors, LLC (871,754 shares), BlackRock, Inc. (832,732 shares), Sofinnova Investments, Inc. (697,916 shares), VANGUARD GROUP INC (588,323 shares), PFM Health Sciences, LP (439,283 shares), Woodline Partners LP (358,436 shares), and Slotnik Capital, LLC (286,962 shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.